The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
Pharmaceutical Impact: The backing of the pharmaceutical industry, specifically those invested in diabetes and obesity management, implicates Tirzepatide in potential shifts within treatment paradigms
PMID: 204 ChenYXuSRenSZhangJXuJSongYet al
However, this hypothesis remains untested in current literature
To combat some of these symptoms, you should follow a few rules when taking this medication
Kilo Verme Etkinlii Klinik Veriler: Ozempic ile ortalama kilo kayb : %10-15 (yksek dozda) Mounjaro ile ortalama kilo kayb : %15-21 (doza bal) Kazanan: Mounjaro , zellikle obezite tedavisinde kilo kayb asndan daha etkili bulunmutur